CRPC w/ Bone Metastases VL

Is There Still a Role for Radium-223? APCCC 2022 Presentation - Neal Shore

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Neal Shore presents the role of radium-223 in the modern treatment armamentarium in metastatic castration-resistant prostate cancer (mCRPC) patients. Biographies: Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, Sout...

Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of the Bones? APCCC 2022 Presentation - Oliver Sartor

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Oliver Sartor presents on the importance of lifestyle and prevention of complications in advanced prostate cancer focusing on how we should take care of our patient’s bones. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Ca...

Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan

Details
Alicia Morgans, Neeraj Agarwal, and Ben Maughan discuss the publication of a study on a combination of enzalutamide and radium-223 that evaluated the utility of bone metabolic markers (BMM) as surrogate markers of response to radium-223 in mCRPC. Biographies: Neeraj Agarwal, MD, Clinical Research Innovation, University of Utah Health - Huntsman Cancer Institute, Salt Lake City, UT Benjamin L. Maug...

Real-World Data in Second-Line Treatment Progressing mCRPC – Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans in a real-world data discussion of advanced prostate cancer beginning with highlighting a recent publication looking at outcomes related to the use of radium versus a second novel hormonal agent. The publication is entitled Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC published in Future Oncol...

Changing the Mechanism of Action in The Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) - Phillip Koo

Details
In conversation with Alicia Morgans, Philip Koo discusses data from a phase II trial that randomized patients to receive radium-223 and sipuleucel-T or sipuleucel-T alone. Dr. Koo explains that patients who received the combination saw a better PSA response, providing evidence for the continued exploration of the combination of radiation and immunotherapy. Biographies: Phillip J. Koo, MD , FACS Di...

Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith

Details
Matthew Smith shares his thoughts on the importance of bone health in the prostate cancer patient population. Osteoporotic or fragility fractures are common due to the age of the patient and long-term androgen deprivation therapy. Fractures have a great impact on patient mortality, mobility, independence, and overall quality of life. Dr. Smith addresses questions regarding bone density measurement...

Real-World Clinical Outcomes with Radium-223 in Metastatic Castration-resistant Prostate Cancer - Neal Shore

Details
Neal Shore joins Alicia Morgans in a discussion on the optimal timing to use radium-223 (Xofigo®) in metastatic castration-resistant prostate cancer (mCRPC). Together they discuss the window of opportunity for administering radium-223 and what we have learned from the ALSYMPCA and ERA-223 trials. Dr. Shore recaps how radium-223 is being used prior to docetaxel and how it is being layered with an a...

Bone Health Agents in Patients with Castrate-Resistant Prostate Cancer - Bertrand Tombal

Details
Neal Shore and Bertrand Tombal discuss the importance of bone health agents, particularly in patients receiving castrate-resistant prostate cancer agents. Highlights of their conversation include the use of antiresorptive therapy to reduce the risk of skeletal-related events in men with bone mCRPC and decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial. Bi...

Assessing the Aging Population and Treatment Considerations for Prostate Cancer - Joe O'Sullivan

Details
At the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Joe O'Sullivan joins Phillip Koo to discuss the onco-geriatric population, why it is referred to as a ticking time bomb, and the unique challenges it presents to the community. Biographies: Joe M. O'Sullivan, MD, FRCPI, FFRRSCI, FRCR, Professor of Radiation Oncology, Queen's University Belfast, Consultant Oncologist, Northern Irela...

The Risk of Dose De-intensifying Treatment, Bone Health in Prostate Cancer - Fred Saad

Details
Alicia Morgans and Fred Saad have a discussion on bone health in prostate cancer patients, an issue for men with advanced prostate cancer and an important topic to keep at the forefront of care. Even though men are living longer, bone metastases increases mortality and impair a person's independence. Fred and Alicia tackle approaching this in your patients, specifically in the metastatic castratio...
email news signup